# Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

> **NCT01833572** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 36 (actual)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01833572
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833572, "Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01833572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*